Guaifenesin Capsules
» Guaifenesin Capsules contain not less than 90.0 percent and not more than 110.0 percent of the labeled amount of guaifenesin (C10H14O4).
Packaging and storage— Preserve in tight containers.
A: Triturate a portion of the contents of Capsules, equivalent to about 100 mg of guaifenesin, with 10 mL of chloroform, filter, and evaporate 1 mL of the filtrate on a watch glass. Mix the residue with 1 drop of formaldehyde and a few drops of sulfuric acid: a deep cherry-red to purple color is produced.
B: The retention time of the guaifenesin peak in the chromatogram of the Assay preparation corresponds to that of the guaifenesin peak in the chromatogram of the Standard preparation as obtained in the Assay.
Dissolution, Procedure for a Pooled Sample 711
Medium: water; 900 mL.
Apparatus 1: 100 rpm.
Time: 45 minutes.
Procedure— Determine the amount of C10H14O4 dissolved, employing the procedure set forth in the Assay, making any necessary modifications.
Tolerances— Not less than 75% (Q) of the labeled amount of C10H14O4 is dissolved in 45 minutes.
Uniformity of dosage units 905: meet the requirements.
Mobile phase, Benzoic acid solution, Resolution solution, Standard preparation, and Chromatographic system Proceed as directed in the Assay under Guaifenesin Tablets.
Assay preparation— Transfer, as completely as possible, the contents of not less than 20 Capsules to a suitable tared container, and determine the average content weight per Capsule. Mix the combined contents, and transfer an accurately weighed portion, equivalent to about 200 mg of guaifenesin, to a 100-mL volumetric flask. Proceed as directed for Assay preparation in the Assay under Guaifenesin Tablets, beginning with “add about 60 mL of water.”
Procedure— Proceed as directed for Procedure in the Assay under Guaifenesin Tablets. Calculate the quantity, in mg, of guaifenesin (C10H14O4) in the portion of Capsule contents taken by the formula:
5C(rU / rS)
in which the terms are as defined therein.
Auxiliary Information— Please check for your question in the FAQs before contacting USP.
Topic/Question Contact Expert Committee
Monograph Clydewyn M. Anthony, Ph.D.
(MDCCA05) Monograph Development-Cough Cold and Analgesics
Reference Standards Lili Wang, Technical Services Scientist
711 Margareth R.C. Marques, Ph.D.
Senior Scientist
(BPC05) Biopharmaceutics05
USP32–NF27 Page 2534
Pharmacopeial Forum: Volume No. 30(1) Page 106
Chromatographic Column—
Chromatographic columns text is not derived from, and not part of, USP 32 or NF 27.